Zynerba Pharmaceuticals (ZYNE)

[dhbuzz]

Love that last paragraph
*****************

Final Thoughts
Zynerba has the potential to provide a therapy for many patients with an unmet need. The upside of Zynerba is massive after considering the potential revenue opportunity compared to its current valuation (market cap of $100 million). I believe that the misunderstanding on the safety of Zygel has created a severe disconnect between the current valuation and potential valuation. This disconnect will likely be rectified in the coming weeks to months with several data readouts due. I anticipate these data readouts will be positive, resulting in price appreciation. At some point, I anticipate they will raise capital, however in the short and long term, I am very bullish on ZYNE. For an outline of expected catalysts, please see Figure 2, and best of luck to all investors!